Breaking News Instant updates and real-time market news.

TASR

Changed name to AAXN

$28.61

-0.32 (-1.11%)

13:33
10/03/16
10/03
13:33
10/03/16
13:33

Justices declined to hear appeal on Taser excessive force case, Reuters says

U.S. Supreme Court let stand a lower court's ruling that police use of a Taser amounted to unconstitutional excessive force in a case involving a mentally ill man who died after being stunned with the electrical weapon, according to Reuters. The justices declined to hear an appeal by the North Carolina village of Pinehurst of a federal appeals court ruling that police can use a Taser only if officers are in immediate danger, the publication said, noting that the 4th U.S. Circuit Court of Appeals found the officers used excessive force in violation of the Constitution's Fourth Amendment. TASER, which manufactures the devices, filed a brief asking the high court to hear the case, the report noted. Reference Link

TASR Changed name to AAXN
$28.61

-0.32 (-1.11%)

10/03/16
LTCO
10/03/16
DOWNGRADE
LTCO
Neutral
TASER downgraded to Neutral from Buy at Ladenburg
10/03/16
CHLM
10/03/16
NO CHANGE
Target $33
CHLM
Buy
Craig-Hallum calls TASER 'leader' in body cams, but notes pricing pressure
Craig-Hallum analyst Steven Dyer said he expects TASER shares to come under pressure after NYPD issued a public hearing notice for a proposed contract for TASER rival Vievu to provide 1,000 body cameras and cloud-based storage for a 1-year pilot program. In "an attempt to remain relevant," it appears Vievu is providing free body cams to 5,000 officers at the beginning and agreed to a "significantly unprofitable contract," contends Dyer, who still views TASER as the "dominant force in the domestic body-worn video market." While he will be watching for downward pressure on future body cam deals, Dyer keeps a Buy rating and $33 price target on TASER shares.
10/03/16
10/03/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Netgear (NTGR) downgraded to Hold from Buy at BWS Financial with analyst Hamed Khorsand saying shares are up approximately 100% this year and are being valued as though there could be a continuous purchasing cycle for the latest products Netgear sells, which he does not believe to be the case. 2. TASER (TASR) downgraded to Neutral from Buy at Ladenburg. 3. Citrix (CTXS) downgraded to Sell from Neutral at UBS with analyst Brent Thill saying he believes the next part of the company's transition will be more difficult reflecting the GoTo spin-off; its fastest growing segment. 4. Robert Half (RHI) downgraded to Underperform from Neutral at Credit Suisse with analyst Anjaneya Singh citing fewer catalysts and increased downside risk in a slowing labor market. 5. Noble Corp. (NE) downgraded to Hold from Buy at Societe Generale with analyst Edward Muztafago citing recent share strength and lower earnings from reduced offshore spending. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
KING
10/03/16
NO CHANGE
Target $32
KING
Buy
TASER 'had no choice but to walk away' from NYPD deal, says CL King
CL King analyst George Godfrey said that according to a source he spoke with the $6.4M police body camera contract awarded by the City of New York may include cameras for as many as 5,000 police officers. If that is correct, TASER had "no choice but to walk away" from this opportunity, but the company still has the opportunity to sell body cameras to the other approximately 29,000 NYC police officers, Godfrey tells investors. The firm keeps a Buy rating and $32 price target on TASER shares, which are down about 14% to $24.62 in early afternoon trading.

TODAY'S FREE FLY STORIES

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:26
06/23/17
06/23
13:26
06/23/17
13:26
Hot Stocks
Portola Pharmaceuticals to resume trading at 1:35 pm ET »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

CHGG

Chegg

$12.44

0.48 (4.01%)

13:25
06/23/17
06/23
13:25
06/23/17
13:25
Recommendations
Chegg analyst commentary  »

Chegg price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
06/23/17
06/23
13:25
06/23/17
13:25
General news
Energy Action: Baker-Hughes »

Energy Action:…

VRX

Valeant

$15.58

0.0801 (0.52%)

13:20
06/23/17
06/23
13:20
06/23/17
13:20
Options
Valeant expiring options active Friday »

Valeant expiring options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

$NSD

NASDAQ Market Internals

13:17
06/23/17
06/23
13:17
06/23/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/23/17
06/23
13:16
06/23/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

13:15
06/23/17
06/23
13:15
06/23/17
13:15
Hot Stocks
Breaking Hot Stocks news story on Cellectis 

Cellectis trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

INFY

Infosys

$14.90

0.13 (0.88%)

13:13
06/23/17
06/23
13:13
06/23/17
13:13
Hot Stocks
Infosys says 'committed no wrongdoing, denies all allegations' in NY tax matter »

Infosys issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

13:08
06/23/17
06/23
13:08
06/23/17
13:08
Hot Stocks
Cellectis to resume trading at 1:15 pm ET »

Cellectis is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:06
06/23/17
06/23
13:06
06/23/17
13:06
Hot Stocks
Portola Pharmaceuticals announces FDA approval of Bevyxxa »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

TRIP

TripAdvisor

$35.74

-0.08 (-0.22%)

13:05
06/23/17
06/23
13:05
06/23/17
13:05
Options
TripAdvisor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
06/23/17
06/23
13:05
06/23/17
13:05
General news
Cleveland Fed hawk Mester didn't discuss policy »

Cleveland Fed hawk Mester…

BHI

Baker Hughes

$54.55

0.025 (0.05%)

13:03
06/23/17
06/23
13:03
06/23/17
13:03
Hot Stocks
Baker Hughes reports U.S. rig count up 8 to 941 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:00
06/23/17
06/23
13:00
06/23/17
13:00
General news
Treasury Action: upcoming supply should put a floor under short rates »

Treasury Action: upcoming…

RIO

Rio Tinto

$39.32

0.61 (1.58%)

, GLNCY

Glencore

$7.10

0.05 (0.71%)

12:59
06/23/17
06/23
12:59
06/23/17
12:59
Hot Stocks
Rio Tinto to give new Glencore C&A proposal 'appropriate consideration' »

Rio Tinto (RIO)…

RIO

Rio Tinto

$39.32

0.61 (1.58%)

GLNCY

Glencore

$7.10

0.05 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$23.15

0.25 (1.09%)

12:56
06/23/17
06/23
12:56
06/23/17
12:56
Hot Stocks
Cellectis announces Calyxt filing of registration statement for proposed IPO »

Cellectis S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PX

Praxair

$133.62

1.15 (0.87%)

12:50
06/23/17
06/23
12:50
06/23/17
12:50
Options
Call spread in Praxair may add to existing bullish position »

Call spread in Praxair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYT

Syngenta

$92.65

0.05 (0.05%)

12:45
06/23/17
06/23
12:45
06/23/17
12:45
Periodicals
Syngenta ordered to pay $217.7M to Kansas farmers in GMO corn case, Reuters says »

A federal jury in Kansas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MT

ArcelorMittal

$21.21

0.315 (1.51%)

12:45
06/23/17
06/23
12:45
06/23/17
12:45
Options
ArcelorMittal call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
06/23/17
06/23
12:45
06/23/17
12:45
General news
Breaking General news story  »

Week of 6/23 Baker-Hughes…

EFA

iShares MSCI EAFE Index Fund

$65.14

0.16 (0.25%)

, VEA

Vanguard Europe Pacific ETF

$41.22

0.089 (0.22%)

12:42
06/23/17
06/23
12:42
06/23/17
12:42
Technical Analysis
On The Fly: ETF fund flow highlights »

For the past week there…

EFA

iShares MSCI EAFE Index Fund

$65.14

0.16 (0.25%)

VEA

Vanguard Europe Pacific ETF

$41.22

0.089 (0.22%)

IEFA

iShares Core MSCI EAFE ETF

$60.83

0.135 (0.22%)

EWJ

iShares MSCI Japan Index Fund

$54.04

-0.05 (-0.09%)

EZU

iShares MSCI Eurozone ETF

$40.44

0.1 (0.25%)

IBB

iShares Nasdaq Biotechnology Index

$320.11

4.01 (1.27%)

IVV

iShares Core S&P 500

$246.13

0.53 (0.22%)

SPY

SPDR S&P 500 ETF Trust

$243.37

0.53 (0.22%)

VO

Vanguard Mid-Cap Index Fund

$143.23

0.561 (0.39%)

VTI

Vanguard Total Stock Market ETF

$125.10

0.36 (0.29%)

VUG

Vanguard Growth Index Fund

$128.93

0.421 (0.33%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.11

0.265 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

12:33
06/23/17
06/23
12:33
06/23/17
12:33
Hot Stocks
Portola FDA label cites secondary endpoint instead of Cohort 1 data, tweet says »

Twitter user…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

VIX

Volatility Index S&P 500 Options

12:30
06/23/17
06/23
12:30
06/23/17
12:30
Options
VIX calls outpace puts nearly 5:1 as the index dips below 10 »

VIX calls outpace puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.55

0.2 (1.62%)

, CACQ

Caesars Acquisition

$19.40

0.15 (0.78%)

12:29
06/23/17
06/23
12:29
06/23/17
12:29
Hot Stocks
Caesars announces effectiveness of S-4 registration statement related to merger »

Caesars Entertainment…

CZR

Caesars

$12.55

0.2 (1.62%)

CACQ

Caesars Acquisition

$19.40

0.15 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLYC

GlycoMimetics

$12.10

-0.03 (-0.25%)

12:28
06/23/17
06/23
12:28
06/23/17
12:28
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.